Satellos Releases Promising Interim Data From Phase 2 TRAILHEAD For SAT-3247 In DMD; Stock Up

India, July 8 -- Satellos Biosciences Inc. (MSLE), a clinical-stage biotechnology company, on Wednesday reported six-month interim data from the Phase 2 TRAILHEAD study for SAT-3247 in treating Duchenne Muscular Dystrophy.

Duchenne Muscular Dystrophy (DMD) is a rare genetic disorder that causes progressive muscle loss. Patients are often diagnosed at birth and face a lifetime of mobility issues as muscle tissue slowly seizes and loses contraction and expansion abilities. The X chromosome-linked disease inordinately effects males and can be addressed to an extent through various gene therapies.

SAT-3247 is an oral, small molecule drug candidate developed using the company's proprietary MyoReGenX platform to regenerate skeletal muscle lost ...